SS Innovations International (NASDAQ: SSII) has reported significant growth in the utilization and global reach of its SSi Mantra surgical robotic system. As of September 8, 2026, the company has completed 14,103 cumulative procedures, a 79% increase from 7,885 at the end of 2025. The installed base of SSi Mantra systems has grown 42% to 238 units, up from 168 at year-end 2025. These figures underscore the accelerating adoption of robotic surgery in markets where access has traditionally been limited.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the platform. The system has been used for more than 170 types of surgical procedures, demonstrating its versatility. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the company's progress in expanding the availability of advanced surgical care across diverse geographies.
In addition to general growth, SS Innovations has reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of August 31, 2026. These include a telesurgery performed over a distance of more than 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, showcasing the system's efficiency and reliability in high-volume settings.
Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. Additionally, SS Innovations believes it can obtain European Union CE marking certification by year-end 2026. These regulatory milestones, if achieved, would open access to two of the world's largest healthcare markets, potentially accelerating revenue growth and further validating the technology.
The implications of this announcement extend beyond the company. The rapid adoption of the SSi Mantra suggests a growing demand for cost-effective robotic surgery solutions, particularly in emerging markets. By making robotic surgery more affordable and accessible, SS Innovations aims to address disparities in surgical care. The company's focus on cardiac procedures and telesurgery also points to a future where specialized surgical expertise can be delivered remotely, improving outcomes in underserved regions.
For investors, the reported growth metrics and upcoming regulatory decisions are key indicators of the company's trajectory. The 79% increase in procedures and 42% expansion of the installed base demonstrate strong commercial momentum. However, the company notes that forward-looking statements involve risks and uncertainties, and actual results may differ materially. For more details, the full report is available at https://ibn.fm/DJILj. The latest news and updates relating to SSII can be found in the company's newsroom at https://ibn.fm/SSII.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The company's product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
